Acoramidis

PALO ALTO, Calif., August 30, 2026 BridgeBio Pharma, Inc. presented new data from the Phase 3 ATTRibute-CM study of...

PALO ALTO, Calif., Aug. 26, 2026 BridgeBio Pharma, Inc. has announced that the first participant has been dosed in...

PALO ALTO, Calif., July 2, 2026 BridgeBio Pharma, Inc. announced new post-hoc analyses published in Circulation: Heart Failure showing...